All the arrangements have now be made for me to go to London on Wednesday to visit the Actors Church where the asbestos artwork will be installed on Tuesday March 24 in the garden outside The Actors’ Church in Covent Garden and will remain there until the end of Wednesday March 25. Without giving too much information away about the piece itself, it will be a glass installation that will have everyone’s messages floating around inside (to replicate the act of a pair of lungs breathing). The fans used to blow the messages around will be turned intermittently on and off so that when they’re resting on the bottom (which will be eye height) people will be able to read them. I had had this invite —–I wanted to let you know the details of the artwork’s launch as it would be wonderful if you would be keen on coming down. Of course all the messages are completely anonymous, but as your message is so emotive I thought it would be wonderful to see you backing the campaign and the artwork. And to also ask if you would be keen to potentially be available for any media interviews – of course we will be able to share any requests well in advance so you can feel prepared and fully brief you on the background of the campaign although your role would purely be to speak about your own personal experience.
I can get there on the Wednesday as Tuesday is my drug day but it has worked well with me getting a Email from Verastem saying.
Our CEO, Robert Forrester, will be in London next week meeting with the COMMAND study investigators. We’ve talked about the two of you getting together and perhaps this could be a good time? He is very motivated by your journey and would be pleased to finally meet you!
Deeply honoured to accept and to be able to chat about Immunotherepy.
There has been a really wonderful report on the Net. Its my Trial and we dont usual get a chance to see such a report. i have sent it to may of my Doctors as they are interested in the report.
Merck (NYSE:MRK) , known as MSD outside the United States and Canada, today announced that new data evaluating KEYTRUDA(R) (pembrolizumab), the company’s anti-PD-1 therapy, in both advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma will be presented as part of the Clinical Trials Plenary Session on Sunday, April 19 at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18 – 22.
The NSCLC data will be the first presentation of new efficacy and safety findings for KEYTRUDA from 495 patients, including validation of PD-L1 expression (abstract #CT104). These data are from the largest, multi-center Phase 1b (KEYNOTE-001) study of an anti-PD-1 therapy. With the mesothelioma findings (abstract #CT103), data evaluating KEYTRUDA will have been presented in eight different types of cancer.
“Our clinical program is investigating the potential of KEYTRUDA in a broad range of cancers where innovative approaches are truly needed – these data to be presented at AACR illustrate this effort,” said Dr. Roger Dansey, senior vice president, Late-Stage Oncology Clinical Development, Merck Research Laboratories. “At AACR, we look forward to sharing new data for KEYTRUDA across a range of challenging cancer types, especially in non-small cell lung cancer and mesothelioma.”
Selected Important Safety Information for KEYTRUDA(R)
Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma receiving KEYTRUDA (the approved indication in the United States), including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively. Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 pneumonitis.
Colitis (including microscopic colitis) occurred in 4 (1%) of 411 patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients respectively, receiving KEYTRUDA. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.
Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients, including a Grade 4 case in 1 (0.2%) patient, receiving KEYTRUDA. Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.
Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3; and permanently discontinue KEYTRUDA for Grade 4 hypophysitis.
Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.
Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients, including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA. Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. Administer corticosteroids for Grade 3 or greater hyperthyroidism. Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids.
Other clinically important immune-mediated adverse reactions can occur. The following clinically significant, immune-mediated adverse reactions occurred in less than 1% of patients treated with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic neuritis, and rhabdomyolysis.
For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement of the adverse reaction to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or less. Permanently discontinue KEYTRUDA for any severe or Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.
Based on its mechanism of action, KEYTRUDA may cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential to use highly effective contraception during treatment and for 4 months after the last dose of KEYTRUDA.
For the treatment of advanced melanoma, KEYTRUDA was discontinued for adverse reactions in 6% of 89 patients who received the recommended dose of 2 mg/kg and 9% of 411 patients across all doses studied. Serious adverse reactions occurred in 36% of patients receiving KEYTRUDA. The most frequent serious adverse drug reactions reported in 2% or more of patients were renal failure, dyspnea, pneumonia, and cellulitis.
The most common adverse reactions (reported in >=20% of patients) were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%).
The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks until disease progression or unacceptable toxicity. No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human milk. Because many drugs are excreted in human milk, instruct women to discontinue nursing during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not been established in pediatric patients.
Please read the link for more Info I just wanted to show the side effects as I found all of that so interesting.
This morning’s smog, viewed from Primrose Hill (Picture: Jeremy Selwyn
A new bill has been introduced in the Senate that claims to improve upon the outdated and flawed Toxic Substance Control Act, but this new piece of legislation fails to address the danger of asbestos in the United States: http://bit.ly/1Bym1EZ
It really is time the Governments do sort all the problems out. The world is so contaminated and we should clean the air up. We must be allowed to breath fresh air.
There are nearly one million documents on microfiche sitting in the office of the Manchester Metropolitan University Business School academic Geoffrey Tweedale. They expose a scandal that ranks among the biggest and costliest of our age: how the Lancashire manufacturing giant Turner & Newall (T&N), once the world’s largest asbestos conglomerate, exposed millions to a lethal carcinogen in full knowledge of its dangers, using PR firms and politicians to hide a truth that it had secretly admitted to in 1961, namely that “the only really safe number of asbestos fibres in the works environment is nil”.
Hidden in this massive archive are documents, revealed here for the first time, which tell the story of corporate recklessness that has led to the deaths of thousands of men and women in Britain who were once exposed to asbestos.
People living in the Spodden Valley area of Rochdale in the 1950s used to joke that they would get frost all year round. The local wood was nicknamed “the snow trees” and even the blackberries picked in late summer were covered with a fine white powder. But the “frost” was no joke – it was asbestos blown from extractor fans at the Turner & Newall factory in the heart of the valley.
Derek Philips never worked there, but for 19 years lived just yards from the site. He played bass in a band with T&N workers and recalls the factory as “the centre of the community”. The guitars hang on the walls of his current home, a static caravan in the Pennine foothills where he waits to die of one of the asbestos-related diseases – meso thelioma, which appears decades after exposure to asbestos and which is killing more than 2,000 people every year in the UK.
His plight has been all too common in Rochdale. In the 1980s the New Statesman reported that on some roads near the factory every second household had lost a family member to asbestos diseases.
“I was diagnosed in October ,” says Philips. “A month later they drained three litres of fluid from my lungs. I couldn’t even stand up properly. I’ve just no chance, have I? I didn’t know about the risks.”
In the coming months, how he was exposed to asbestos and who he was working for at that time will become vital issues as lawyers fight to win compensation for Derek.
I hate to hear how people have to go through these fights. Other people have been through the fight it should really be speeded up more.
Please read the rest of the story through the link
Another wonderful story told by a Australian Mesothelioma Warrior
I have my own Newspaper now I have to play around with it as I dont know all the little extras but here it is.